About this Journal Submit a Manuscript Table of Contents
Journal of Amino Acids
Volume 2012 (2012), Article ID 356081, 13 pages
Review Article

Drosophila Answers to TDP-43 Proteinopathies

1Department of Life Sciences, University of Trieste, Via A. Valerio 28, 34127 Trieste, Italy
2International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149 Trieste, Italy

Received 5 December 2011; Accepted 23 January 2012

Academic Editor: Yijuang Chern

Copyright © 2012 Maurizio Romano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Initially implicated in the pathogenesis of CFTR and HIV-1 transcription, nuclear factor TDP-43 was subsequently found to be involved in the origin and development of several neurodegenerative diseases. In 2006, in fact, it was reported for the first time the cytoplasmic accumulation of TDP-43 in ubiquitin-positive inclusions of ALS and FTLD patients, suggesting the presence of a shared underlying mechanism for these diseases. Today, different animal models of TDP-43 proteinopathies are available in rodents, nematodes, fishes, and flies. Although these models recapitulate several of the pathological features found in patients, the mechanisms underpinning the progressive neuronal loss observed in TDP-43 proteinopathies remain to be characterized. Compared to other models, Drosophila are appealing because they combine the presence of a sophisticated brain with the possibility to investigate quickly and massively phenotypic genetic modifiers as well as possible therapeutic strategies. At present, the development of TDP-43-related Drosophila models has further strengthened the hypothesis that both TDP-43 “loss-of-function” and “gain-of-function” mechanisms can contribute to disease. The aim of this paper is to describe and compare the results obtained in a series of transgenic and knockout flies, along with the information they have generated, towards a better understanding of the mechanisms underlying TDP-43 proteinopathies.

1. Introduction

Nowadays, Drosophila is one of the most widely used model organism for studying complex genetic and biological problems. Drosophila was introduced as an experimental model in the early twentieth century. Although there are several different Drosophila species which differ in habitat, morphology, and genetic background, D. melanogaster is the species with the highest degree of homology with humans. Over the years, many mutants of Drosophila melanogaster have been isolated and many transgenic strains have been created as model systems for the study of human disease [1], leading to the observation that more than 70% of human loci correlated with pathological conditions have orthologs in Drosophila melanogaster [2]. Compared to other animal models used to study the mechanisms underlying many disease onset/progression, Drosophila present several advantages: the life span is short (from 40 to 120 days) [3]; the genome is compact, with only 4 pairs of homologous chromosomes and roughly 13600 genes [4]. The importance of Drosophila melanogaster is further supported by the fact that it represents an animal model where the efficacy of putative therapeutic agents can be quickly screened and tested [1, 5]. Altogether, therefore, these characteristics make Drosophila an ideal model for gaining insights into the mechanisms by which genes cause disease in humans.

In particular, in the last ten years increasing attention has turned towards this animal in order to obtain a better understanding of neurodegenerative disorders [1, 5]. For this purpose, the most appealing feature of this organism consists in its high neuronal complexity, derived from an advanced brain capable of learning and memory, as well as from the presence of a nervous system made up of several specialized cytotypes belonging to ion channels, receptors, and neurotransmitters that are present also in humans. In conclusion, the degree of conservation between humans and flies has allowed to model consistently several human neurodegenerative disorders in the Drosophila brain [20].

Among genes implicated in human disease, TDP-43 is a nuclear factor recently identified as a protein capable of playing a crucial role in the pathogenesis of FTLD, ALS, and other neurodegenerative diseases [2124]. In ALS and FTLD patients, in fact, this protein (and its C-terminal fragments) has been found as the major components of preferentially cytoplasmic phosphorylated inclusions positive for ubiquitin and tau/α-synuclein negative [25, 26]. The mechanisms through which these inclusions may be connected with disease are still the subjects of debate [27].

However, the fact that they may be acting as a cytoplasmic protein “sink” to trap the predominantly nuclear TDP-43 has suggested that the onset of neurodegenerative diseases might be the consequence of the progressive nuclear loss of function of TDP-43 trapped within the cytoplasmic inclusions (this does not rule out, of course, that various “gain-of-function” mechanisms may be playing a role in parallel) [22].

In order to clarify these issues it is therefore important to find a suitable animal model that expresses a functional homologue of human TDP-43. In this respect, it is already known that the TDP-43 ortholog of Drosophila melanogaster (namely, TBPH) has the structure and in vitro functions similar to the human protein, at least for the repression of splicing of specific exons [36, 37]. Therefore, in consideration of this considerable homology between human and fruit fly TDP-43 orthologs there is a growing interest in utilizing Drosophilas as a model to characterize the functions of this protein. Here, we will review the various flies models that have been developed up to now to investigate the pathological hallmarks of the neurodegenerative diseases related to alterations of expression of wild-type or mutant TDP-43/TBPH.

2. Structural Divergences and Functional Conservation between TDP-43 and TBPH

The TARDBP gene is a highly conserved gene throughout evolution and orthologs of human TDP-43 have been found in all higher eukaryotic species, including Drosophila melanogaster. In flies, the main homologue of human TDP-43 is a protein called TBPH (UniProt, O97468_DROME). The comparison of the longest protein isoforms shows that the region that includes two RNA recognition motifs (RRM1 and RRM2, Figure 1(a)) is more conserved than the C-terminal region (Figure 1(b)). In fact, pairwise amino acid alignment highlights the presence of 59% identity and 77% similarity between human and fruit fly N-terminals/RRMs, whereas the degree of identity and similarity of the C-terminus regions is only 18% and 22%, respectively.

Figure 1: Comparison between human and fly TDP43. (a) Schematic representation of each domain (and amino acid position) in the two orthologs. (b) Alignment of the human (TDP-43) and fly (TBPH) proteins. The longest isoforms of human and fly proteins were used for this analysis (Uniprot accession no. Q13148 and O97468, resp.). Amino acids identical (∣) or similar (:) between the two proteins are indicated. Bold residues indicate the RNA recognition domains, RRM1 and RRM2. The RNP consensus sequences present in each RRM are highlighted (bold and underlined). All potential phosphorylation sites within human TDP-43 are indicated by asterisks. Importantly different studies have found a strong link between hyperphosphorylation at Serine379, Serine403, Serine404, Serine409, Serine410, and the inclusions of TDP-43 in FTLD-U/ALS [2834].

Notwithstanding these differences, many experiments have highlighted an extremely high degree of functional similarity and interchangeability between the human and fly proteins (see also below). First of all, both proteins share the same preference with regards to RNA binding specificities as recent studies have shown that TBPH is able to preferentially bind the same consensus (UG)n rich sequences tagged by the human ortholog [36]. Importantly, it has also been shown that TBPH has splicing inhibitory effects overlapping those of human TDP-43 both in vitro and in vivo. For example, in vitro assays have demonstrated that the Drosophila TDP-43 ortholog was able to interfere with CFTR exon splicing minigenes similarly to TDP-43 [36]. Even more strikingly, and similarly to what has been observed for the human protein [37, 38], the TBPH mutant without the C-terminal region lost this inhibitory activity. This observation has provided the first evidence that many, if not all, characterized functions of TDP-43, are common both for the human and fly protein and even extend to the same protein regions. In keeping with this view, subsequent in vivo studies have confirmed that C-terminal region of TBPH, despite its structural and sequence divergence from TDP-43, can also interact with the same nuclear partners of TDP-43 (i.e., hnRNPA2, hnRNPA1, hnRNPC, and hnRNPB1) [37].

Altogether, therefore, these observations indicate that there is an extremely high degree of functional conservation through evolution from flies to human and this observation has represented the starting point for using Drosophila models to address the issue of TDP-43-dependant neurodegeneration.

3. TBPH Null Allele Drosophilas

Two complimentary approaches have been utilized for the genetic characterization of ALS-related pathways: loss and gain of function of the Drosophila TDP-43 ortholog and overexpression of TDP-43 variants presenting mutations found in ALS patients. Tables 1 and 2 summarize the TDP-43 knocked out and transgenic flies so far generated and the most relevant phenotypic features observed in these models.

Table 1: Flies models of TDP-43 proteinopathies. Elav-GAL4 and 1407-GAL4 are pan-neuronal drivers; GMR-Gal4 driver is eye specific. D42-Gal4 driver is specific for motor neurons; OK107-GAL4 driver is specific for mushroom body. MHC-GAL4 and 24B-GAL4 drivers are muscle specific; Repo-GAL4 driver is glia specific.
Table 2: Ectopic expression of TDP-43 mutants.

4. Loss-of-Function Models

With regards to loss of function, the general strategy has been to target disruption of the TBPH gene in Drosophila in order to analyze whether ALS-like phenotypes could be generated.

The first TBPH-ko model used chromosomal deletions that removed the initial part of the gene regulatory region and the ORF [6]. Homozygous TBPH-ko flies were viable after embryogenesis and most of them were able to reach the pupal stage and undergo metamorphosis [6]. It was hypothesized that the progression through the first stages of developments is probably due to the permanence of residual gametic TBPH. However, a high percentage of TBPH-/-flies were unable to complete eclosion and remained trapped inside the pupal cages. Furthermore, TBPH-ko flies presented a dramatic decrease in flight and walking performances with spastic and uncoordinated movements [6]. As a result, the life span of these flies was significantly reduced. The analysis of presynaptic terminals at neuromuscular junctions (NMJs) highlighted that the TBPH-/-larvae show a reduction of axonal branches and synaptic boutons present inside the muscles [6].

The second loss-of-function model was generated with a point mutation (G>A) that introduced a stop codon at residue 367 (Q367X) [7]. The semilethality of the homozygosity for TBPH deletion was confirmed by flies homozygous for the Q367X allele or flies treated with tubulin-Gal4-TBPH RNAi knockdown [7]. This study showed that TBPH can regulate dendritic branching in ddaE and ddaF neurons. In fact, whereas TBPH silencing (both by homozygosity for Q367X mutation or by whole-body RNAi) decreased dendritic branching, TBPH overexpression had the opposite results [7].

Most importantly, both studies demonstrated that the functions of the human TDP-43 overlapped those of TBPH also in vivo. In fact, it was shown that overexpression of TDP-43 could efficiently rescue the phenotype caused by TBPH deficiency.

A third null allele model of TBPH was generated by deleting the whole coding sequence of the TBPH gene [9]. Contrary to what was observed in previous reports, homozygous TBPH -/- flies died at the second instar larval stage. It should be noted, however, that this null allele model was used only to confirm in vivo the data obtained in vitro with human cell lines and no further molecular characterization was carried out. In particular, this model was used to confirm that the ability of TDP-43 to bind and regulate expression of the HDAC6 mRNA was conserved also by TBPH in Drosophila [9]. In conclusion, a proper comparison with the two previous models will have to await for a more extensive characterization of this model.

Finally, a fourth null allele model of TBPH was created by deletion of 932 bp within the 5′ end of TBPH [17]. Similarly to the other models [6, 7], early lethal phenotype with alteration of locomotion was observed both in larvae and in the adult flies. On the other hand, the number of the synaptic boutons in the NMJ of these flies was increased (while it was decreased in the other models). The reasons for this discrepancy remain still unknown.

Taken together, these studies suggest that the genetic background can significantly modulate or modify the effects of the genomic mutations. However, all these initial reports are strongly in agreement that depletion of TDP-43/TBPH can trigger neurodegeneration.

5. TDP-43 Transgenic Flies

As intuitively obvious, a complimentary approach to the creation of TBPH-ko flies consists in the ubiquitous or tissue-specific overexpression and/or silencing of this factor by using the Gal4-UAS system. Consistently, different reports found that the expression of the wild-type form of TDP-43 (both TBPH and TDP-43) in the Drosophila eye causes a severe retinal degeneration with loss of cells [1013, 18].

In a likewise manner, expression of TDP-43 in mushroom bodies caused neuronal death and axonal loss [11] and overexpression of TDP-43 in motor neurons caused morphological and functional defects associated with cytoplasmic and axonal aggregation as well as axonal swelling [11]. Different TDP-43 toxicity has been also associated with its subcellular accumulation. For example, it was shown that cytoplasmic accumulation of TDP-43 is sufficient to induce degeneration in neuronal and nonneuronal tissues [12, 18]. Cytoplasmic inclusions of TDP-43 were toxic in eyes, muscles, and glia, whereas both cytoplasmic or nuclear TDP-43 accumulation were toxic in neurons of adult flies [18]. Finally, in some cases the ectopic expression of TDP-43 in eyes led to the detection of nuclear detergent-insoluble high-molecular-weight TDP-43 aggregates [11, 12]. Similarly to what is observed in mammalian systems [39, 40], TDP-43 toxicity was associated with increased levels of both nuclear and cytoplasmic TDP-43, independently from the presence of inclusions [18]. Indeed, a consistent observation in different reports was that the ectopic TDP-43 expression led to a dose- and age-dependent toxicity. In fact, the onset time and the severity of locomotion defects and neuronal loss were proportional to the levels of TDP-43 expression [8, 10, 11, 13, 18].

Another distinguishing feature of TDP-43 proteinopathies is the presence of mutations occurring mainly within the C-terminal region of the TDP-43 protein (that have been identified mostly in both sporadic ALS and FALS patients [41]). Overexpression of artificial or disease-related TDP-43 mutants displayed variable levels of toxicity (see Table 1) probably depending on the exact level of overexpression with respect to wild-type protein. In fact, it is quite challenging to separate the eventual toxic effects of the mutation with respect to the general toxicity induced by TDP-43 overexpression. The expression of the ALS/FTLD-linked TDP-43 mutations A315T and M337V in flies resulted in an increased neurodegeneration (Table 2) [7, 8, 12, 13, 15], consistently with the phenotypes exhibited by the transgenic rodent models for the same mutations [39, 42, 43]. On the other hand, other disease-causing mutations expression in flies caused a variable increment of toxicity (Table 2) [7, 8, 13, 15].

Other types of more artificial mutations, however, were found to be more consistent with regards to their effects. For example, this was the case for the impact of mutations within the nuclear localization and nuclear export sequences. In general, while the expression of the TDP-43 NLS-mutant in the fly eyes resulted in a stronger [12, 18] or comparable [8] degenerative phenotype compared to the effects of the TDP-43 wild-type expression, the TDP-43 NES-mutant was associated with a normal phenotype [12, 18].

Finally, and most importantly, it is clear that the RNA-binding activity of TDP-43 is crucial for TDP-43 toxicity [8, 11, 19], whereas the C-terminal end seems to have milder impact on longevity, neuronal loss, and locomotion [8].

6. Genetic Interactions with TDP-43 in Drosophila

A growing body of evidence indicates that TDP-43 abnormalities are not limited to ALS and FTLD but are present in many neurodegenerative and myodegenerative diseases [4446]. Of course, several other genes have also been implicated in the pathogenesis of these diseases. Different studies have therefore addressed the problem of possible interactions between TDP-43 and some of these genes, in order to highlight the presence of common pathologic pathways or the existence of genetic modifiers of disease severity [41, 4752].

The Valosin-Containing Protein (VCP) is a molecular chaperone VCP that segregates ubiquitinated substrates from multimeric protein complexes. Autosomal dominant mutations in the VCP gene have been identified in the Inclusion Body Myopathy associated with Paget’s disease of bone and frontotemporal dementia (IBMPFD; MIM167320). Mutations in this gene exhibit variable penetrance and cause progressive muscular bony and neuronal degeneration with lethal exitus [53]. Most importantly, TDP-43 has been found within ubiquitinated cytoplasmic inclusions in the muscles of IBMPFD patients [44, 47]. In order to identify genes able to suppress neurodegeneration, a genetic screening was undertaken in a Drosophila model of IBMPFD created with disease-causing VCP mutations [12]. In this way, a genetic interaction between VCP and TDP-43 was highlighted (Figure 2(a)). In this model, it was observed that (1) the expression of pathogenic VCP mutants caused cytoplasmic TDP-43 accumulation in vivo; (2) the intracellular redistribution of TDP-43 was sufficient to induce degeneration; (3) enhancement of toxicity was obtained following coexpression of the TDP-M337V mutant with mutant dVCP [12]. These findings are consistent with a knockin IBMPFD mouse model that exhibited progressive cytoplasmic accumulation of TDP-43 and ubiquitin-positive inclusion bodies in quadriceps myofibrils and brain [48]. Thus, both animals apparently represent useful models for preclinical studies regarding this pathology.

Figure 2: Genetic interactions of TDP-43/TBPH. (a) Schematic representation describing the effects of valosin-containing protein (VCP7) gene overexpression on TDP-43-toxicity in Drosophila melanogaster. (b) Schematic representation describing the effects of FUS/TLS gene overexpression on TDP-43-toxicity in Drosophila melanogaster. (c) Schematic representation describing the effects of UBQLN gene overexpression on TDP-43-toxicity in Drosophila melanogaster. The lines of evidence supporting the genetic interaction between the TDP-43 and these other genes are schematically summarized.

Another gene found mutated in familial and sporadic ALS is the one coding for fused in sarcoma/translocated-in-liposarcoma (FUS/TLS) protein [54, 55]. Similarly to TDP-43, FUS/TLS is a nuclear RNA-binding protein ubiquitously expressed [41]. Several ALS-causing mutations in this protein cause the redistribution of the protein to the cytoplasm and this accumulation leads to the formation of cytoplasmic inclusions in neurons and glial cells [5456]. The coexistence of FUS- and TDP43-immunoreactive inclusions in an ALS patient carrying the TDP-43 G298S mutation suggested the FUS/TLS and TDP-43 might share some pathologic mechanisms leading to ALS [57]. Subsequent studies demonstrated that FUS/TLS and TDP-43 interact physically and functionally [41, 58, 59]. To better investigate this interaction, two Drosophila models of FUS/TLS-mediated ALS were obtained by generating a null allele of the fly FUS/TLS ortholog [60] and by expressing mutant human FUS/TLS in eyes and motor neurons [15]. In these models, the genetic interaction between FUS/TLS and TDP-43 was demonstrated through the worsening of neurodegenerative phenotypes following coexpression of wild-type or mutant FUS/TLS and wild-type or mutant TDP-43 [15, 60] (Figure 2(b)). Furthermore, it was confirmed that also the FUS and TDP-43 fly orthologs associate with each other in an RNA-dependent complex [60] as reported for the human proteins [50, 58, 61].

Finally, recent studies have found that ubiquilin 1 (UBQLN) is another potential TDP-43 interactor [62]. UBQLN is a cytosolic protein involved in targeting misfolded proteins to the proteasome for degradation [63] and implicated in the pathogenesis of some neurodegenerative diseases [64, 65]. Experiments in mammalian cells showed that TDP-43 and UBQLN colocalize in cytosolic aggregates [62] and suggested that UBQLN might be involved in pathway controlling TDP-43 degradation. In order to investigate its genetic interaction with UBQLN, a Drosophila model of TDP-43 proteinopathy was generated (Figure 2(c)). Contrarily to expectations, however, coexpression of UBQLN increased the toxicity of TDP-43 without aggregation although the levels of TDP-43 were decreased and these results were further confirmed also in a mammalian cell line [10].

Taken together, these observations provide evidence that many aspects of neurodegeneration are conserved from Drosophila to vertebrates and strengthen the utilization of the Drosophila models to study systematically modulators of TDP-43-induced neurodegeneration.

7. Genes and Proteins Regulated by TBPH in Drosophila

At present, not many TBPH-interacting molecules have been identified that can possess a direct link with disease. Two exceptions are represented by the validated interaction between TBPH and the HDAC6 and futsch mRNAs (Figure 3).

Figure 3: HDAC6 and futsch levels are controlled by TBPH in Drosophila. Two genes are currently described as direct targets of TBPH in Drosophila melanogaster. Both HDAC6 and futsch mRNAs are bound by TBPH. In particular, TBPH silencing decreases HDAC6 mRNA and, as a consequence, protein levels. On the other hand, TBPH silencing causes a drop only in futsch protein levels but not in mRNA expression, suggesting in this case an involvement of TDP-43 in either the mRNA transport or translations systems.

The histone deacetylase 6 (HDAC6) gene has been implicated in the pathogenesis of Alzheimer’s disease and Parkinson’s disease by linking together two protein degradation pathways (the ubiquitin proteasome system and autophagy) [6669]. Recently, HDAC6 mRNA was identified as the first molecular target of TDP-43 conserved both in mammalian and invertebrates [9]. The levels of HDAC6 mRNA and protein decreased upon TDP-43 silencing and this effect was associated with accumulation of acetyl-tubulin, the major HDAC6 substrate [9]. It should also be noted that follow-up studies found that TDP-43 and FUS/TLS form a complex with HDAC6 [61]. These findings, therefore, suggested the possibility that alterations of TDP-43 or FUS/TLS might deregulate HDAC6 functions and this event could be crucial for ALS pathogenesis.

In parallel, starting from the observation by different research groups that the loss of TBPH in Drosophila alters the morphological organization of the NMJ [6, 13, 17], further molecular characterization of the first model of TBPH-ko Drosophilas focused on possible alterations of elements important for the cytoskeletal organization at synaptic level. Among all the tested proteins, a consistent reduction in the protein levels of futsch was observed in the heads of TBPH -/- flies [19]. The Futsch protein is a homolog of human MAP1B necessary for proper axonal and dendritic growth [70]. In this study, it was shown that the TBPH protein directly interacts with futsch mRNA without affecting its stability or splicing profile. However, since futsch protein levels were decreased in TBPH -/- animals, this observation suggested that TBPH might be somehow involved in the posttranscriptional regulation of futsch expression [19]. This observation provided additional insights into the physiological roles of TDP-43 and into the potential mechanisms underlying ALS and the neurodegenerative diseases associated with alteration of TDP-43.

8. Concluding Remarks

Altogether, the studies with Drosophila models have allowed us to make several general observations.(1)The data gained so far from these models significatively overlap most of the observations made in human patients and in rodent models, so strengthening the usefulness of the fruit fly in investigating the role played by TDP-43 protein abnormalities in ALS and other neurodegenerative diseases.(2)Similarly to what is observed in rodent models, both overexpression and silencing of TDP-43/TBPH in Drosophila produce neurodegeneration. Beyond the particular attention that must be reserved to the expression levels of TDP-43 mutants, whose effect should be tested specifically for any model, these observations also suggest that events able to modify the expression of TDP-43 in humans might elicit neuronal dysfunctions even before the appearance of pathological TDP-43 inclusions.

While Drosophila models confirm that toxicity occurs regardless of inclusions, the relevance of the cytoplasmic accumulation for the pathology remains an open question. In flies, expression of mutants accumulating in the cytoplasm showed an increase in toxicity, but a NLS mutant TDP-43 expressed in C. elegans, although cytoplasmic, did not result in alteration of locomotion and this observation led to the suggestion that nucleus is the primary site of the TDP-43 toxicity [71].(1)Different Drosophila models support the hypothesis that TDP-43 toxicity depends also on retaining the ability to bind RNA targets [8, 11, 19]. This observation further strengthens the hypothesis that the “loss of function” within nuclei is crucial for development of the disorder.(2)The carboxy-terminal domain seems to have a prominent role in the pathogenesis of human diseases. In fact, most mutations found in patients lie within this domain (for a recent review see [28]). Intriguingly, although the C-terminal domain is quite different in human and fly, the splicing regulation by human and Drosophila TDP-43 requires its presence. In fact, both TDP-43 and TBPH mutants devoid of this region lack splicing-modifying capacity. Therefore, although the structural conservation of this region is low in human and flies, some functions potentially associated with neurodegeneration have certainly been conserved through evolution.(3)Several studies have addressed the pathogenic role of hyperphosphorylation on the formation of TDP-43 inclusions [2834]. It should be noted that none of the potential phosphorylated sites within the C-terminal region is conserved in flies (Figure 1(b)). However, Drosophila along with cellular models were also created to investigate this aspect by expressing human TDP-43 carboxyl terminal fragment [16]. Contrary to the previous, this study has suggested that phosphorylation occurs after aggregation and that aggregation propensity of TDP-43 could be reduced by hyperphosphorylation. The discrepancy between these results and previous studies could be ascribed to the different systems used for the characterizations.(4)Age-dependent degeneration is an important feature of neurodegenerative diseases. The investigations aimed at understanding the relevance of aging in affecting TDP-43 expression in humans and its possible association with Alzheimer were not conclusive [72]. At present, some of the Drosophila models of TDP-43-pathologies described in this paper support the hypothesis that aging can impact on the neurodegeneration caused by this nuclear factor [11, 13, 17]. However, additional studies are required to understand how many observation made in these flies models regarding this particular issues can be generalized to humans.

For all these reasons, fruit flies remain an appealing system in which to continue the characterization of the pathogenesis of TDP-43 proteinopathies through the screening of modifier genes or the search for drugs useful for the prevention and cure of neurodegenerative diseases.


ALS:Amyotrophic lateral sclerosis
FTLD:Frontotemporal lobar degeneration
NMJ:Neuromuscular juction
IBMPFD:Inclusion body myopathy associated with Paget’s disease of bone and/or frontotemporal dementia
UBQLN:Ubiquilin 1
FUS/TLS:Fused in sarcoma/translocated-in-liposarcoma
HDAC6:histone deacetylase 6
TDP-43:TAR-DNA binding Protein-43
TBPH:TAR-DNA binding Protein Homologue.


The authors thank Professor Francisco Baralle for helpful suggestions and comments. This work was supported by “University of Trieste-Finanziamento per Ricercatori di Ateneo” and AriSLA.


  1. J. Bilen and N. M. Bonini, “Drosophila as a model for human neurodegenerative disease,” Annual Review of Genetics, vol. 39, pp. 153–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. T. Reiter, L. Potocki, S. Chien, M. Gribskov, and E. Bier, “A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster,” Genome Research, vol. 11, no. 6, pp. 1114–1125, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. D. W. Piper, D. Skorupa, and L. Partridge, “Diet, metabolism and lifespan in Drosophila,” Experimental Gerontology, vol. 40, no. 11, pp. 857–862, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. M. Rubin, M. D. Yandell, J. R. Wortman et al., “Comparative genomics of the eukaryotes,” Science, vol. 287, no. 5461, pp. 2204–2215, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Shulman, L. M. Shulman, W. J. Weiner, and M. B. Feany, “From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease,” Current Opinion in Neurology, vol. 16, no. 4, pp. 443–449, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Feiguin, V. K. Godena, G. Romano, A. D'Ambrogio, R. Klima, and F. E. Baralle, “Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior,” The FEBS Letters, vol. 583, no. 10, pp. 1586–1592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Lu, J. Ferris, and F. B. Gao, “Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching,” Molecular Brain, vol. 2, no. 1, article 30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Voigt, D. Herholz, F. C. Fiesel et al., “TDP-43-mediated neuron loss in vivo requires RNA-binding activity,” PLoS ONE, vol. 5, no. 8, Article ID e12247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. F. C. Fiesel, A. Voigt, S. S. Weber et al., “Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6,” The EMBO Journal, vol. 29, no. 1, pp. 209–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. A. Hanson, S. H. Kim, D. A. Wassarman, and R. S. Tibbetts, “Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS),” Journal of Biological Chemistry, vol. 285, no. 15, pp. 11068–11072, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Li, P. Ray, and E. J. Rao, “A Drosophila model for TDP-43 proteinopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3169–3174, 2010.
  12. G. P. Ritson, S. K. Custer, B. D. Freibaum et al., “TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97,” Journal of Neuroscience, vol. 30, no. 22, pp. 7729–7739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. S. Estes, A. Boehringer, R. Zwick, J. E. Tang, B. Grigsby, and D. C. Zarnescu, “Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS,” Human Molecular Genetics, vol. 20, no. 12, pp. 2308–2321, 2011. View at Publisher · View at Google Scholar
  14. W. Guo, Y. Chen, X. Zhou et al., “An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity,” Nature Structural & Molecular Biology, vol. 18, no. 7, pp. 822–830, 2011.
  15. N. A. Lanson Jr., A. Maltare, H. King et al., “A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43,” Human Molecular Genetics, vol. 20, no. 13, pp. 2510–2523, 2011. View at Publisher · View at Google Scholar
  16. H.-Y. Li, P.-A. Yeh, H.-C. Chiu, C.-Y. Tang, and B. P. Tu, “Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation,” PLoS ONE, vol. 6, no. 8, Article ID e23075, 2011. View at Publisher · View at Google Scholar
  17. M.-J. Lin, C.-W. Cheng, and C.-K. J. Shen, “Neuronal function and dysfunction of Drosophila dTDP,” PLoS ONE, vol. 6, no. 6, Article ID e20371, 2011. View at Publisher · View at Google Scholar
  18. L. Miguel, T. Frébourg, D. Campion, and M. Lecourtois, “Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies,” Neurobiology of Disease, vol. 41, no. 2, pp. 398–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. V. K. Godena, G. Romano, M. Romano et al., “TDP-43 regulates Drosophila neuromuscular junctions growth by modulating futsch/MAP1B levels and synaptic microtubules organization,” PLoS ONE, vol. 6, no. 3, Article ID e17808, 2011. View at Publisher · View at Google Scholar
  20. F. Rodrigues, I. Schmidt, and C. Klämbt, “Comparing peripheral glial cell differentiation in Drosophila and vertebrates,” Cellular and Molecular Life Sciences, vol. 68, pp. 55–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. I. F. Wang, L. S. Wu, and C. K. J. Shen, “TDP-43: an emerging new player in neurodegenerative diseases,” Trends in Molecular Medicine, vol. 14, no. 11, pp. 479–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Buratti and F. E. Baralle, “Chapter 1 the molecular links between TDP-43 dysfunction and neurodegeneration,” Advances in Genetics, vol. 66, pp. 1–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Seelaar, J. D. Rohrer, Y. A. L. Pijnenburg, N. C. Fox, and J. C. van Swieten, “Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, pp. 476–486, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. J. Strong and W. Yang, “The frontotemporal syndromes of ALS. Clinicopathological correlates,” Journal of Molecular Neuroscience, vol. 45, no. 3, pp. 648–655, 2011. View at Publisher · View at Google Scholar
  25. M. Neumann, D. M. Sampathu, L. K. Kwong et al., “Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Science, vol. 314, no. 5796, pp. 130–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Arai, M. Hasegawa, H. Akiyama et al., “TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Biochemical and Biophysical Research Communications, vol. 351, no. 3, pp. 602–611, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. H. Baloh, “TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration,” The FEBS Journal, vol. 278, no. 19, pp. 3539–3549, 2011. View at Publisher · View at Google Scholar
  28. M. Hasegawa, T. Arai, T. Nonaka et al., “Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Annals of Neurology, vol. 64, no. 1, pp. 60–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Inukai, T. Nonaka, T. Arai et al., “Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS,” The FEBS Letters, vol. 582, no. 19, pp. 2899–2904, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Arai, I. R. A. Mackenzie, M. Hasegawa et al., “Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies,” Acta Neuropathologica, vol. 117, no. 2, pp. 125–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. M. Igaz, L. K. Kwong, A. Chen-Plotkin et al., “Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies,” Journal of Biological Chemistry, vol. 284, no. 13, pp. 8516–8524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Kametani, T. Nonaka, T. Suzuki et al., “Identification of casein kinase-1 phosphorylation sites on TDP-43,” Biochemical and Biophysical Research Communications, vol. 382, no. 2, pp. 405–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Neumann, L. K. Kwong, E. B. Lee et al., “Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies,” Acta Neuropathologica, vol. 117, no. 2, pp. 137–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Nonaka, T. Arai, E. Buratti, F. E. Baralle, H. Akiyama, and M. Hasegawa, “Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells,” The FEBS Letters, vol. 583, no. 2, pp. 394–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Buratti and F. E. Baralle, “Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9,” The Journal of Biological Chemistry, vol. 276, pp. 36337–36343, 2001.
  36. Y. M. Ayala, S. Pantano, A. D'Ambrogio et al., “Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function,” Journal of Molecular Biology, vol. 348, no. 3, pp. 575–588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. D'Ambrogio, E. Buratti, C. Stuani et al., “Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo,” Nucleic Acids Research, vol. 37, no. 12, pp. 4116–4126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Buratti, A. Brindisi, M. Giombi, S. Tisminetzky, Y. M. Ayala, and F. E. Baralle, “TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing,” Journal of Biological Chemistry, vol. 280, no. 45, pp. 37572–37584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Wegorzewska, S. Bell, N. J. Cairns, T. M. Miller, and R. H. Baloh, “TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18809–18814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. F. Gendron, K. A. Josephs, and L. Petrucelli, “Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration,” Neuropathology and Applied Neurobiology, vol. 36, no. 2, pp. 97–112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Lagier-Tourenne, M. Polymenidou, and D. W. Cleveland, “TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration,” Human Molecular Genetics, vol. 19, no. 1, Article ID ddq137, pp. R46–R64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. N. R. Stallings, K. Puttaparthi, C. M. Luther, D. K. Burns, and J. L. Elliott, “Progressive motor weakness in transgenic mice expressing human TDP-43,” Neurobiology of Disease, vol. 40, no. 2, pp. 404–414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Zhou, C. Huang, H. Chen et al., “Transgenic rat model of neurodegeneration caused by mutation in the TDP gene,” PLoS Genetics, vol. 6, no. 3, Article ID e1000887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. C. C. Weihl, P. Temiz, S. E. Miller et al., “TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 10, pp. 1186–1189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Cook, Y. J. Zhang, Y. F. Xu, D. W. Dickson, and L. Petrucelli, “TDP-43 in neurodegenerative disorders,” Expert Opinion on Biological Therapy, vol. 8, no. 7, pp. 969–978, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. A. S. Chen-Plotkin, V. M. Y. Lee, and J. Q. Trojanowski, “TAR DNA-binding protein 43 in neurodegenerative disease,” Nature Reviews Neurology, vol. 6, no. 4, pp. 211–220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. C. Weihl, A. Pestronk, and V. E. Kimonis, “Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia,” Neuromuscular Disorders, vol. 19, no. 5, pp. 308–315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Badadani, A. Nalbandian, G. D. Watts et al., “VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease,” PLoS ONE, vol. 5, no. 10, Article ID e13183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. S. K. Custer, M. Neumann, H. Lu, A. C. Wright, and J. P. Taylor, “Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone,” Human Molecular Genetics, vol. 19, no. 9, Article ID ddq050, pp. 1741–1755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. C. Ling, C. P. Albuquerque, J. S. Han et al., “ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13318–13323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. I. R. A. Mackenzie, R. Rademakers, and M. Neumann, “TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia,” The Lancet Neurology, vol. 9, no. 10, pp. 995–1007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Maruyama, H. Morino, H. Ito et al., “Mutations of optineurin in amyotrophic lateral sclerosis,” Nature, vol. 465, no. 7295, pp. 223–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. B. Guinto, G. P. Ritson, P. J. Taylor, and M. S. Forman, “Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy,” Acta Neuropathologica, vol. 114, no. 1, pp. 55–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. T. J. Kwiatkowski, D. A. Bosco, A. L. LeClerc et al., “Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis,” Science, vol. 323, no. 5918, pp. 1205–1208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Vance, B. Rogelj, T. Hortobágyi et al., “Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6,” Science, vol. 323, no. 5918, pp. 1208–1211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Dormann and C. Haass, “TDP-43 and FUS: a nuclear affair,” Trends in Neurosciences, vol. 34, no. 7, pp. 339–348, 2011. View at Publisher · View at Google Scholar
  57. H. X. Deng, H. Zhai, E. H. Bigio et al., “FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis,” Annals of Neurology, vol. 67, no. 6, pp. 739–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. B. D. Freibaum, R. K. Chitta, A. A. High, and J. P. Taylor, “Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery,” Journal of Proteome Research, vol. 9, no. 2, pp. 1104–1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. C. F. Sephton, C. Cenik, A. Kucukural et al., “Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1204–1215, 2011. View at Publisher · View at Google Scholar
  60. J.-W. Wang, J. R. Brent, A. Tomlinson, N. A. Shneider, and B. D. McCabe, “The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 4118–4126, 2011. View at Publisher · View at Google Scholar
  61. S. H. Kim, N. P. Shanware, M. J. Bowler, and R. S. Tibbetts, “Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA,” Journal of Biological Chemistry, vol. 285, no. 44, pp. 34097–34105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. S. H. Kim, Y. Shi, K. A. Hanson et al., “Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1,” Journal of Biological Chemistry, vol. 284, no. 12, pp. 8083–8092, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. H. S. Ko, T. Uehara, K. Tsuruma, and Y. Nomura, “Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains,” The FEBS Letters, vol. 566, no. 1–3, pp. 110–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. A. L. Mah, G. Perry, M. A. Smith, and M. J. Monteiro, “Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation,” Journal of Cell Biology, vol. 151, no. 4, pp. 847–862, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Doi, K. Mitsui, M. Kurosawa, Y. MacHida, Y. Kuroiwa, and N. Nukina, “Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates,” The FEBS Letters, vol. 571, no. 1–3, pp. 171–176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. U. B. Pandey, Y. Batlevi, E. H. Baehrecke, and J. P. Taylor, “Erratum: HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration,” Autophagy, vol. 3, no. 6, pp. 643–645, 2007. View at Scopus
  67. U. B. Pandey, Z. Nie, Y. Batlevi et al., “HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS,” Nature, vol. 447, no. 7146, pp. 859–863, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Du, X. Liu, X. Chen et al., “Drosophila histone deacetylase 6 protects dopaminergic neurons against α-synuclein toxicity by promoting inclusion formation,” Molecular Biology of the Cell, vol. 21, no. 13, pp. 2128–2137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Y. Lee, H. Koga, Y. Kawaguchi et al., “HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy,” The EMBO Journal, vol. 29, no. 5, pp. 969–980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Hummel, K. Krukkert, J. Roos, G. Davis, and C. Klämbt, “Drosophila Futsch/22C10 is a MAP1B-like protein required for dendritic and axonal development,” Neuron, vol. 26, no. 2, pp. 357–370, 2000. View at Scopus
  71. P. E. Ash, Y. J. Zhang, C. M. Roberts et al., “Neurotoxic effects of TDP-43 overexpression in C. elegans,” Human Molecular Genetics, vol. 19, no. 16, Article ID ddq230, pp. 3206–3218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. A. C. Wilson, B. N. Dugger, D. W. Dickson, and D.-S. Wang, “TDP-43 in aging and Alzheimer's disease—a review,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 2, pp. 147–155, 2011.